OTCPK:NEVP.F

Stock Analysis Report

Executive Summary

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has NeuroVive Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NEVP.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.2%

NEVP.F

3.5%

US Biotechs

2.4%

US Market


1 Year Return

-48.2%

NEVP.F

4.6%

US Biotechs

-10.0%

US Market

Return vs Industry: NEVP.F underperformed the US Biotechs industry which returned 1.9% over the past year.

Return vs Market: NEVP.F underperformed the US Market which returned -13.3% over the past year.


Shareholder returns

NEVP.FIndustryMarket
7 Day3.2%3.5%2.4%
30 Day-12.7%-3.2%-11.0%
90 Day-40.0%-2.4%-19.4%
1 Year-48.2%-48.2%5.4%4.6%-8.1%-10.0%
3 Yearn/a19.3%16.3%17.3%9.6%
5 Year-98.4%-98.4%-4.4%-8.9%36.1%21.1%

Price Volatility Vs. Market

How volatile is NeuroVive Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NeuroVive Pharmaceutical undervalued compared to its fair value and its price relative to the market?

1.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NEVP.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NEVP.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NEVP.F is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: NEVP.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NEVP.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NEVP.F is good value based on its PB Ratio (1x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is NeuroVive Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-7.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEVP.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NEVP.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NEVP.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NEVP.F's revenue is expected to decline over the next 3 years (-25.2% per year).

High Growth Revenue: NEVP.F's revenue is forecast to decline over the next 3 years (-25.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NEVP.F is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has NeuroVive Pharmaceutical performed over the past 5 years?

-0.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NEVP.F is currently unprofitable.

Growing Profit Margin: NEVP.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NEVP.F is unprofitable, and losses have increased over the past 5 years at a rate of -0.8% per year.

Accelerating Growth: Unable to compare NEVP.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEVP.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: NEVP.F has a negative Return on Equity (-60.25%), as it is currently unprofitable.


Next Steps

Financial Health

How is NeuroVive Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: NEVP.F's short term assets (SEK59.9M) exceed its short term liabilities (SEK20.3M).

Long Term Liabilities: NEVP.F's short term assets (SEK59.9M) exceed its long term liabilities (SEK361.0K).


Debt to Equity History and Analysis

Debt Level: NEVP.F is debt free.

Reducing Debt: NEVP.F has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NEVP.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NEVP.F has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -2.6% each year.


Next Steps

Dividend

What is NeuroVive Pharmaceutical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NEVP.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NEVP.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NEVP.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NEVP.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NEVP.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Erik Kinnmann (61yo)

4.08s

Tenure

kr3,905,000

Compensation

Mr. Erik Kinnmann, M.D., Ph.D., M.B.A., Assoc. Prof. has been the Chief Executive Officer of NeuroVive Pharmaceutical AB since March 14, 2016. Mr. Kinnmann served as the Chief Medical Officer of Infant Bac ...


CEO Compensation Analysis

Compensation vs Market: Erik's total compensation ($USD385.68K) is below average for companies of similar size in the US market ($USD622.20K).

Compensation vs Earnings: Erik's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Erik Kinnmann
Chief Executive Officer4.08yrskr3.91m0.22% SEK29.2k
Catharina Johansson
CFO & VP of Investor Relations6.33yrsno data0.032% SEK4.4k
Eskil Elmér
Chief Scientific Officer & VP of Discovery20.25yrskr247.00k0.31% SEK42.2k
Daniel Schale
Director of Communications2.5yrsno datano data
Magnus Hansson
Chief Medical Officer and VP of Preclinical & Clinical Development4.25yrsno data0.22% SEK30.2k
Lars Vedin
Consultantno datano datano data

4.3yrs

Average Tenure

50.5yo

Average Age

Experienced Management: NEVP.F's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Laskow-Pooley
Chairman of the Board2.42yrskr430.00k0.016% SEK2.2k
David Bejker
Director3.25yrskr329.00k0.016% SEK2.2k
Jan Törnell
Director3.25yrskr280.00k0.016% SEK2.2k
Gunnar Magnus Modée Persson
Director1yrno datano data
Denise Goode
Director2yrskr193.00kno data

2.4yrs

Average Tenure

59yo

Average Age

Experienced Board: NEVP.F's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 118%.


Top Shareholders

Company Information

NeuroVive Pharmaceutical AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NeuroVive Pharmaceutical AB
  • Ticker: NEVP.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr137.419m
  • Listing Market Cap: kr13.572m
  • Shares outstanding: 185.95m
  • Website: https://www.neurovive.com

Number of Employees


Location

  • NeuroVive Pharmaceutical AB
  • Medicon Village
  • Scheelevägen 2
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NVP BTAOM (OMX Nordic Exchange Stockholm)NPV BTA 062020SESEKNo data
NVPOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKOct 2008
0QDULSE (London Stock Exchange)YesShare CapitalGBSEKOct 2008
NTPDB (Deutsche Boerse AG)YesShare CapitalDEEUROct 2008
NEVP.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDOct 2008
NVPSBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBSEKOct 2008

Biography

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. NeuroVive Pharmaceutical AB has a partnership with TRACK-TBI; and has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 06:23
End of Day Share Price2020/04/06 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.